Institution
Eastern Cooperative Oncology Group
Facility•Philadelphia, Pennsylvania, United States•
About: Eastern Cooperative Oncology Group is a facility organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 249 authors who have published 170 publications receiving 26514 citations. The organization is also known as: ECOG.
Topics: Cancer, Breast cancer, Chemotherapy, Leukemia, Hazard ratio
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Changes in immunologic parameters associated with IFNalpha2b treatment and dosage that may account for some of the differences in the clinical efficacy of this modality are demonstrated.
Abstract: BACKGROUND
The clinical antitumor activity of recombinant interferon α2b (IFNα2b) has been well documented in patients with advanced and high-risk melanoma; however, its mechanism of action remains conjectural. Trial E2690 evaluated the immunomodulatory effects of IFNα2b in vivo during treatment at high doses (the HDI arm; n = 51 patients) and at low doses (the LDI arm; n = 54 patients) in relation to standard observation (OBS; n = 43 patients).
METHODS
This study evaluated peripheral blood lymphocytes (PBLs) for phenotypic markers and cytotoxic functions at 1 month, 3 months, and 12 months in the HDI arm, the LDI arm, and the OBS arm and examined correlations between changes observed in PBLs or in tumors with regard to treatment dosage and disease outcome. Tumor biopsy samples were studied for response to IFNα2b at a range of concentrations in vitro.
RESULTS
Baseline blood phenotypic and functional assays did not predict disease outcome; however, modulation of these immunologic assays by IFNα2b treatment was observed and was associated with IFNα2b dosage. Tumor cell class II major histocompatibility antigen expression (human leukocyte/lymphocyte antigen DR) and adhesion molecule expression (ICAM-1) were modulated by exposure to IFNα2b in a dose dependent manner. Blood natural killer (NK) cell function, T-cell function, and subset distribution were modulated early by patients in the HDI arm and later by patients in the LDI arm. None of the variables tested in these studies predicted recurrence free survival. The numbers of patients studied were smaller than may be needed to detect potentially clinically significant changes.
CONCLUSIONS
These data demonstrate changes in immunologic parameters associated with IFNα2b treatment and dosage that may account for some of the differences in the clinical efficacy of this modality. The current results also suggest the need for further study of newer molecular intermediates of IFNα2b and T-cell response to specific antigens of melanoma. Cancer 2002;95:1101–12. © 2002 American Cancer Society.
DOI 10.1002/cncr.10775
88 citations
••
The Royal Marsden NHS Foundation Trust1, University of Texas MD Anderson Cancer Center2, Cardiff University3, Oslo University Hospital4, Northwestern University5, Monash University6, Flinders Medical Centre7, National Institutes of Health8, University of Oxford9, Eastern Cooperative Oncology Group10, University College Hospital11, Institute of Cancer Research12, University of Hamburg13
TL;DR: Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.
Abstract: PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naive advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naive advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.
86 citations
••
TL;DR: It is concluded that the incidence of the Ph chromosome in AML is very low, although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.
Abstract: Evaluable karyotypes were available in 776 of 1148 adult patients who were entered on acute myeloid leukemia (AML) treatment protocols of the Eastern Cooperative Oncology Group. Among these, we found seven patients (0.9%) with t(9;22)(q34;q11), the Philadelphia (Ph) chromosome, in bone marrow metaphases. All fulfilled the FAB criteria for AML (three M0, two M1, two M2), although one patient presented with an additional, distinct lymphoid blast cell population. Chromosomal aberrations in addition to the Ph chromosome were seen in four patients (including two cases of monosomy 7). Molecular analysis by polymerase chain reaction in four patients tested revealed variable BCR/ABL transcript forms (ela2, b2a2, b3a2, b2a3+e1a2). By immunophenotyping, all seven patients were myeloid based on the overall antigen expression pattern. However, all but one demonstrated lymphoid-associated antigens on the myeloid blast cells. The six evaluable patients failed to respond to treatment with a standard anthracycline/cytosine arabinoside-containing regimen. We conclude that the incidence of the Ph chromosome in AML is very low. Although both genotypically and phenotypically heterogenous, Ph chromosome-positive AML, represents a clinically distinct entity with poor outcome.
86 citations
•
Medical College of Wisconsin1, University of Cambridge2, University of Texas MD Anderson Cancer Center3, Eastern Cooperative Oncology Group4, St. Vincent's Health System5, Imperial College London6, Leipzig University7, University of South Carolina8, Donauspital9, University of Copenhagen10, University of Toronto11, University College London12, University of Bordeaux13, Case Western Reserve University14
TL;DR: Comparing 3-year leukemia-free survival in comparable subjects receiving chemotherapy or a transplant indicates better LFS with HLA-identical sibling transplants than chemotherapy in some persons with AML in 2nd remission.
Abstract: The best therapy for persons with acute myelogenous leukemia (AML) in 2nd remission is unknown. Bone marrow transplants from an HLA-identical sibling are reported to be better than chemotherapy but this is controversial. The objective of the study was to compare 3-year leukemia-free survival (LFS) in comparable subjects receiving chemotherapy or a transplant. 485 persons with AML in 2nd remission were studied. The chemotherapy cohort included 244 persons treated on trials of the British Medical Research Council, Eastern Cooperative Oncology Group and MD Anderson Hospital. The transplant cohort included 257 persons transplanted worldwide and reported to the international Bone Marrow Transplant Registry (16 were also chemotherapy subjects.) Subjects were selected for comparable age and year of treatment. Preliminary analyses identified two factors correlated with LFS: age 30 years and 1st remission duration 1 year; subsequent analyses were partitioned accordingly. Three-year probabilities of treatment-related mortality with chemotherapy and transplants were 7% (95% confidence interval, 3-15%) vs 56% (49-63%). Three-year leukemia relapse probabilities were 81% (74-86%) vs 41% (33-49%). Three-year probabilities of LFS were 17% (12-23%) vs 26 (20-32%). Cohort analysis showed significantly higher LFS with transplants vs chemotherapy in persons 1 year (41% (29-53%) vs 17% (7-32%); P = 0.017) and those in > 30 years with 1st remissions < or = 1 year (18% (9-29%) vs 7% (2-16%); P = 0.046). Others had comparable LFS with both treatments. These data indicate better LFS with HLA-identical sibling transplants than chemotherapy in some persons with AML in 2nd remission.
84 citations
••
TL;DR: A collaborative study with the hope of resolving some of the controversies regarding the criteria and methods for the subclassification of follicular lymphomas found that the patient population could be separated into at least two prognostic groups, for SNC and/or LNC and for S NC + LNC + LC cells.
80 citations
Authors
Showing all 249 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Cella | 156 | 1258 | 106402 |
Donna Neuberg | 135 | 810 | 72653 |
Stanley R. Hamilton | 126 | 441 | 94831 |
Martin S. Tallman | 117 | 917 | 60011 |
Al B. Benson | 113 | 578 | 48364 |
Richard Gray | 109 | 808 | 78580 |
David H. Johnson | 103 | 488 | 55925 |
Nancy E. Davidson | 99 | 384 | 63544 |
Michael A. Carducci | 91 | 574 | 39457 |
George P. Canellos | 88 | 343 | 32151 |
Hillard M. Lazarus | 88 | 575 | 31572 |
John M. Bennett | 88 | 458 | 54128 |
Antonio C. Wolff | 82 | 378 | 41408 |
Rebecca Gelman | 81 | 283 | 34736 |
Edward A. Stadtmauer | 81 | 427 | 28392 |